1. Home
  2. OMER vs HTBK Comparison

OMER vs HTBK Comparison

Compare OMER & HTBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OMER
  • HTBK
  • Stock Information
  • Founded
  • OMER 1994
  • HTBK 1997
  • Country
  • OMER United States
  • HTBK United States
  • Employees
  • OMER N/A
  • HTBK N/A
  • Industry
  • OMER Biotechnology: Pharmaceutical Preparations
  • HTBK Major Banks
  • Sector
  • OMER Health Care
  • HTBK Finance
  • Exchange
  • OMER Nasdaq
  • HTBK Nasdaq
  • Market Cap
  • OMER 579.5M
  • HTBK 566.4M
  • IPO Year
  • OMER 2009
  • HTBK 1998
  • Fundamental
  • Price
  • OMER $9.33
  • HTBK $9.22
  • Analyst Decision
  • OMER Buy
  • HTBK Buy
  • Analyst Count
  • OMER 4
  • HTBK 2
  • Target Price
  • OMER $22.50
  • HTBK $11.75
  • AVG Volume (30 Days)
  • OMER 1.1M
  • HTBK 325.7K
  • Earning Date
  • OMER 11-13-2024
  • HTBK 01-31-2025
  • Dividend Yield
  • OMER N/A
  • HTBK 5.64%
  • EPS Growth
  • OMER N/A
  • HTBK N/A
  • EPS
  • OMER N/A
  • HTBK 0.71
  • Revenue
  • OMER N/A
  • HTBK $169,172,000.00
  • Revenue This Year
  • OMER N/A
  • HTBK N/A
  • Revenue Next Year
  • OMER N/A
  • HTBK $5.68
  • P/E Ratio
  • OMER N/A
  • HTBK $13.06
  • Revenue Growth
  • OMER N/A
  • HTBK N/A
  • 52 Week Low
  • OMER $2.61
  • HTBK $7.66
  • 52 Week High
  • OMER $13.60
  • HTBK $11.27
  • Technical
  • Relative Strength Index (RSI)
  • OMER 49.55
  • HTBK 40.20
  • Support Level
  • OMER $8.21
  • HTBK $9.07
  • Resistance Level
  • OMER $11.26
  • HTBK $9.29
  • Average True Range (ATR)
  • OMER 0.93
  • HTBK 0.24
  • MACD
  • OMER -0.20
  • HTBK 0.03
  • Stochastic Oscillator
  • OMER 31.37
  • HTBK 61.22

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

About HTBK Heritage Commerce Corp

Heritage Commerce Corp operates as a bank holding company. The company, through its subsidiary, offers commercial banking services to small and medium-sized businesses and their owners, managers, and employees. It operates through two segments, namely Banking and Factoring. The bank generates its revenue from the Banking segment.

Share on Social Networks: